A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.